RICHLAND, Wash.--(BUSINESS WIRE)--IsoRay, Inc. (“IsoRay”) (OTCBB:ISRY), a medical isotope company focusing on brachytherapy solutions for prostate and other malignant tissue cancers through use of its proprietary Cesium-131 radioisotope, announced its financial results for the second quarter of fiscal year 2007, ended December 31, 2006.
